Idifarma Desarrollo Farmacéutico, S.L.

Independent, privately-owned pharmaceutical CDMO based in Spain and specialized in highly potent drugs. Staff of 90+ people and over 100 international clients. Range of services covering from first pre-formulation trials to commercial manufacturing: drug formulation, development and validation of analytical methods, quality control and batch release in the EU, stability studies, regulatory affairs, GMP contract manufacturing and packaging for clinical or commercial use.

State-of-the-art facilities with high containment plant for GMP manufacturing of oral solid dosage forms, for both highly potent and non-potent drugs.

Poligono Mocholi C/ Noáin, 1 - 31110 Noáin (Navarra), NV 31110
Tel: +34 948 214 023

PharmTech News Articles

FDA issued a warning letter to Cixi Zhixin Bird Clean-Care Product Co., Ltd for violations of cGMP for finished pharmaceuticals.

The company announced an investment in a new facility in Dundalk, County Louth, Ireland.

Pharmco Laboratories received an FDA warning letter for significant violations of CGMP for finished drugs and APIs at its Florida, US facility as well as misbranding of over-the-counter (OTC) acne and sunscreen drug products.

Novo Nordisk entered a research collaboration with the University of Oxford focused on Type 2 diabetes.